

Envoltórios Bacterianos (BTC5901)

Lipopolissacarídeos


Grupo 01:

Nayara Del Santos


Filipe Barbalho

Mirla Henostroza


Lucas Guimarães



O QUE É O LPS?




ESTRUTURA DO LPS




Sua estrutura é composta por uma parte **hidrofóbica (antígeno A)**, e a parte hidrofílica ou **cadeia O**.

FUNÇÕES DO LPS




- ✓ Conferir carga à porção externa do envoltório Gram-negativa (Impede a entrada livre de compostos hidrofóbicos na célula, incluindo antibióticos);
- ✓ Assimetria da membrana externa (Permite a adoção de conformação de β -barril pelas proteínas da membrana externa);
- ✓ Interação bactéria-hospedeiro via sistema imune (Tanto em relações parasíticas, patógenos, quanto mutualísticas, microbiota intestinal);
- ✓ Proteção contra sais biliares.

MECANISMO DE RESPOSTA PIROGÊNICA




FATORES DE VIRULÊNCIA BACTERIANA



Estratégias de virulência em bactérias


Mecanismos de patogenicidade: Aderência e invasão, evasão das defesas do hospedeiro, captação de nutrientes e **produção de citocinas**.

RECONHECIMENTO DO LPS PELO SISTEMA IMUNE



- Ativação das vias de sinalização (transcrição NF κ B);
- Sinalização variada para outras células do organismo (neutrófilos, linfócitos B).

ESTRUTURA, SÍNTESE E TRANSPORTE DO LPS




(1) Padayatti, P. S.; Lee, S. C.; Stanfield, R. L.; Wen, P. C.; Tajkhorshid, E.; Wilson, I. A.; Zhang, Q. Structural Insights into the Lipid A Transport Pathway in MsbA. *Structure* 2019, 27 (7), 1114–1123.e3. <https://doi.org/10.1016/j.str.2019.04.007>.

Lipídeo A


- **Funções e Interações**

- Endotoxina
- Porção anfipática que permite a ancoragem na membrana externa- Cadeias acil + fosfato
- Causador de choque séptico




Síntese




Lipídeo A - Via de Raetz





Modificação do Lipídeo A



Inibidores da síntese de lipídeo A







RJPXD33 (TNLYMLPKWDIP)



A. *E. coli* W3110

B. *E. coli* W3110RL



Legenda

- 1- tobramicina
- 2- L-161,240
- 3- CHIR-090
- 4- ciprofloxacina


Jenkins, R. J.; Dotson, G. D. Dual Targeting Antibacterial Peptide Inhibitor of Early Lipid A Biosynthesis. *ACS Chem. Biol.* 2012, 7 (7), 1170–1177. <https://doi.org/10.1021/cb300094a>.

Barb, AW et al. Inhibition of Lipid A Biosynthesis as the Primary Mechanism of CHIR-090 Antibiotic Activity in *Escherichia coli*. *Biochemistry.* 2007 March 27; 46(12): 3793–3802. doi:10.1021/bi6025165.


Polissacarídeo Cerne

- **Funções e Interações**



- Interação com anticorpos que ativam o sistema complemento
- Normalmente Espécie-específico
- Manutenção da homeostase celular



Síntese




Mudança de fase (Phase variation)



Clark, S. E.; Eichelberger, K. R.; Weiser, J. N. Evasion of Killing by Human Antibody and Complement through Multiple Variations in the Surface Oligosaccharide of Haemophilus Influenzae. Mol. Microbiol. 2013, 88 (3), 603–618.
<https://doi.org/10.1111/mmi.12214>.


Polissacarídeo O-específico




- **Funções e Interações**
 - Resistência ao complemento- impede o acesso ao polissacarídeo cerne
 - Marcador antigênico sorovariante-específico (*E. coli*, *Salmonella*)
 - Reconhecimento por bacteriófagos
 - Resistência à fagocitose

Vias de síntese do polissacarídeo O


Wzy-dependent




ABC-dependent




Synthase-dependent



Transporte até a Membrana Externa





Simpson BW, May JM, Sherman DJ, Kahne D, Ruiz N. 2015 Lipopolysaccharide transport to the cell surface: biosynthesis and extraction from the inner membrane. Phil. Trans. R. Soc. B 370: 20150029. <http://dx.doi.org/10.1098/rstb.2015.0029>




Simpson BW, May JM, Sherman DJ, Kahne D, Ruiz N. 2015 Lipopolysaccharide transport to the cell surface: biosynthesis and extraction from the inner membrane. *Phil. Trans. R. Soc. B* 370: 20150029. <http://dx.doi.org/10.1098/rstb.2015.0029>

MsbA: transportador de drogas anfipáticas




Siarheyeva, A.; Sharom, F. J. The ABC Transporter MsbA Interacts with Lipid A and Amphipathic Drugs at Different Sites. *Biochem. J.* 2009, 419 (2), 317–328. <https://doi.org/10.1042/BJ20081364>.

Nocaute de MsbA



Alexander, M. K.; Miu, A.; Oh, A.; Reichelt, M.; Ho, H.; Chalouni, C.; Labadie, S.; Wang, L.; Liang, J.; Nickerson, N. N.; et al. Disrupting Gram-Negative Bacterial Outer Membrane Biosynthesis through Inhibition of the Lipopolysaccharide Transporter MsbA. Antimicrob. Agents Chemother. 2018, 62 (11), 1–15. <https://doi.org/10.1128/AAC.01142-18>.

Nocaute de MsbA




Alexander, M. K.; Miu, A.; Oh, A.; Reichelt, M.; Ho, H.; Chalouni, C.; Labadie, S.; Wang, L.; Liang, J.; Nickerson, N. N.; et al. Disrupting Gram-Negative Bacterial Outer Membrane Biosynthesis through Inhibition of the Lipopolysaccharide Transporter MsbA. *Antimicrob. Agents Chemother.* 2018, 62 (11), 1–15. <https://doi.org/10.1128/AAC.01142-18>.


Inibição de MsbA

Ho, H.; Miu, A.; Alexander, M. K.; Garcia, N. K.; Oh, A.; Zilberleyb, I.; Reichelt, M.; Austin, C. D.; Tam, C.; Shriver, S.; et al. Structural Basis for Dual-Mode Inhibition of the ABC Transporter MsbA. *Nature* 2018, 557 (7704), 196–201.

<https://doi.org/10.1038/s41586-018-0083-5>.



APLICAÇÕES DO LPS



Quantificação do LPS

Avoiding animal use



Rabbit Pyrogen
Test



Monocyte Activation
Test




Limulus Amebocyte
Lysate



Recombinant Factor C
Assay



LC-MS² Endotoxin
detection




Pyrogen Detection
Immunologic response



No LER



Potential interferences



Endotoxin Detection
Enzymatic response



Potential LER



Potential interferences



Endotoxin Detection
Chemical quantification




No LER



No interferences

Quantificação do LPS



(FUKUMORI, 2008)



Endotoxinas na Farmacopéia

Como método de detecção de endotoxinas bacterianas, o ensaio de LAL foi pela primeira vez introduzido na USP XX (1980). No Brasil, foi incluso na 4a. Edição da Farmacopéia em 1996.

Importante não só para IFA mas como componentes da cadeia produtiva, em especial para vias parenterais.

Limites de Endotoxina definidos a partir da quantidade a ser aplicada no paciente, UE (Unidade de Endotoxina)

Endotoxinas na Farmacopéia

Farmacopeia Brasileira, 6ª edição PB050-00

VACINA HEPATITE B (RECOMBINANTE)

Vaccinum hepatitis B ADN recombinatum

TESTES DE SEGURANÇA BIOLÓGICA

Esterilidade (5.5.3.2.1). Proceder conforme descrito na monografia de *Vacinas para uso humano*.

Pirrogênios (5.5.2.1). Cumpre o teste.

Endotoxinas bacterianas (5.5.2.2). No máximo 10 UE/mL.

An improved whole cell pertussis vaccine with reduced content of endotoxin


Waldely Oliveira Dias,^{1,*} Arno A.J. van der Ark,² Maria Aparecida Sakauchi,³ Flávia Saldanha Kubrusly,¹ Ana Fabíola R.O. Prestes,¹ Monamaris Marques Borges,⁴ Noemi Furuyama,³ Denise S.P.Q. Horton,⁴ Wagner Quintilio,⁵ Marta Antoniazzi,⁶ Betsy Kuipers,² Bernard A.M. van der Zeijst² and Isaías Raw¹

¹Center of Biotechnology; Instituto Butantan; São Paulo, Brazil; ²Research and Development; Netherlands Vaccine Institute (NVI)/ National Institute for Public Health and the Environment (RIVM); Bilthoven, Utrecht the Netherlands; ³Division of Technological Development and Production; Instituto Butantan; São Paulo, Brazil; ⁴Laboratory of Bacteriology; Instituto Butantan; São Paulo, Brazil; ⁵Quality Control Service; Instituto Butantan; São Paulo, Brazil; ⁶Laboratory of Genetic; Instituto Butantan; São Paulo, Brazil


Table 1. Quantitative analysis of LOS content and activity of 15 batches of Plow and bulk products in the GC and LAL assay, respectively


	Plow	wP	p (t-Test)
LOS content ($\mu\text{g LOS/mg protein}$)	5.27 ± 0.88	6.57 ± 0.87	< 0.001*
Proportion of O-linked fatty acyl chains (C10:0-3OH/C14:0-3OH/C14:0)	0.9/2.2/1.0	0.9/2.2/1.0	
Endotoxin activity (IU endotoxin/mg protein)	15,380 $\pm$ 13,851	533,317 $\pm$ 259,915	< 0.001**

*t-Test assuming equal variances; **t-Test assuming unequal variances.



(DIAS et al., 2013)







(DIAS et al., 2013)

Monofosforil Lipídio A

Monophosphoryl lipid A



Lipolysaccharide



(ARENAS, 2012)

Referências (Aplicações)

ARENAS, J. The Role of Bacterial Lipopolysaccharides as Immune Modulator in Vaccine and Drug Development.

Endocrine, Metabolic & Immune Disorders-Drug Targets, v. 12, n. 3, p. 221–235, 2012.

CASELLA, C. R.; MITCHELL, T. C. Putting endotoxin to work for us: MPLA as clinical adjuvant. **Cell Mol Life Sci**, v. 65, n. 20, p. 3231–3240, 2008.

DIAS, W. O.; ARK, A. A. J. VAN DER; SAKAUCHI, M. A.; et al. An improved whole cell pertussis vaccine with reduced content of endotoxin. **Human Vaccines and Immunotherapeutics**, v. 9, n. 2, p. 339–348, 2013.

FUKUMORI, N. T. O. Determinação de endotoxina bacteriana (pirogênio) em radiofármacos pelo método de formação de gel. validação. , p. 77, 2008.

Vídeo

<https://twitter.com/nature/status/906759694445940736>